UGA joins initiative to advance US biotech manufacturing: National Institute for Innovation of Manufacturing Biopharmaceuticals

The University of Georgia is partnering in a biopharmaceutical innovation institute that aims to boost market production of cell-based therapies and develop a skilled workforce trained for the biotechnology and pharmaceutical industry.

The newly created public-private partnership, called the National Institute for Innovation of Manufacturing Biopharmaceuticals, or NIIMBL, will focus its efforts on driving down the cost and risks associated with manufacturing advanced cell and gene therapies for biopharmaceutical production.

Steven Stice, director of the University of Georgia’s Regenerative Bioscience Center, is the UGA lead in the partnership, which is coordinated by the University of Delaware.

The NIIMBL mission is to accelerate biopharmaceutical manufacturing innovation, support the development of standards that enable more efficient and rapid manufacturing capabilities, and educate and train a world-leading biopharmaceutical manufacturing workforce, fundamentally advancing U.S. competitiveness in this industry.

  • Boston Children's TransLab
  • Carnegie Mellon University
  • Clemson University
  • Dana-Farber Cancer Institute
  • Delaware State University
  • Duke University
  • Emory University
  • Georgia Institute of Technology
  • Johns Hopkins University
  • Massachusetts Institute of Technology
  • Memorial Sloan Kettering Cancer Center
  • Northeastern University
  • North Carolina State University
  • Pennsylvania State University
  • Purdue University
  • Rensselaer Polytechnic Institute
  • Tulane University
  • University of Colorado
  • University of Connecticut
  • University of Delaware
  • University of Iowa
  • University of Georgia
  • University of Kansas
  • University of Kentucky
  • University of Maryland
  • University of Massachusetts
  • University of Minnesota
  • University of North Carolina
  • University of Pennsylvania
  • University of Texas
  • University of Wisconsin
  • Worcester Polytechnic Institute

NIIMBL represents a total investment of $250 million, including $129 million in private cost-share commitments from the NIIMBL consortium of 150 companies, nonprofits, educational institutions and state partners across the country, combined with at least $70 million in federal funding from the U.S. Department of Commerce.

UGA is a Tier One Partner and will be led by RBC director Steven Stice, a Georgia Research Alliance Eminent Scholar and D.W. Brooks Distinguished Professor in the College of Agricultural and Environmental Sciences. Stice will facilitate team assembly for response to the project calls, leveraging years of collective experience in regenerative medicine and technology development.

He is co-director of the Regenerative Engineering and Medicine research center, or REM, a collaboration of Emory University, the Georgia Institute of Technology and UGA, which will play a pivotal role in developing new ideas and technologies.

NIIMBL Companies and Non-Profit Organizations

Agilent Technologies, AIChE, Air Liquide, Altimmune, Amgen, Amgen Foundation, Artemis Biosystems, Association of University Research Parks, ASTM, BioFactura, Biogen, BioHealth Innovation, Biologics Modular, BioPhorum Operations Group, bioVolutions, BMC Corp, Boehringer Ingelheim Fremont, California Manufacturing Technology Consulting, Celgene Corp, Charles River Laboratories, ChromaTan, Cimetrics, Colorado BioScience Association, Commissioning Agents, Inc, Connecting Connecticut's Science Community, Continuus Pharma, Corning Life Sciences, DelawareBio, DEMEP, DVIRC, Eli Lilly Research Labs, EMD Serono, FiberCell Systems, FloDesign Sonics, Fraunhofer CMB, Fraunhofer CESE, GBSI, GE Healthcare Life Sciences, Georgia Bio, Georgia Tech MEP, Grifols S.A., IBM, ILC Dover, ImmunoGen, Indiana Health Industry Forum, Institute for BioScience & Biotechnology Research, Intellia Therapeutics, IOWABio, Janssen Pharma, Juno Therapeutics, Kentucky Life Sciences Council, LakePharma, Lewa Process Technologies, Lonza Biologics Inc., Manex, MANTEC, MassBio, MassMep, MD MEP, MedImmune, MEPOL, MilliporeSigma, National Institute for Pharmaceutical Technology and Education, NC Bio, NC MEP, NEPIRC, NewYorkBIO, North Carolina Biotechnology Center, Novartis, Novo Nordisk, NYDSTI, Orochem, Pall Corp, Parental Drug Association, PBS Biotech, Pennsylvania Bio, Pfizer, Pharma Matrix, Pharyx Inc., Protein Sciences Corp, Purdue MEP, Regeneron Pharma, RepliGen, Rooster Bio, Sanofi Pasteur, SC MEP, Shire, Southwest Research Institute, SoyMeds, Stratosphere, Sudhin Biopharma, Tech Council of MD, Terumo BCT, THBI, Thrive Bioscience, University City Science Center, Unum Therapeutics, USP, Vericel Corp, Voyager Therapeutics, VWR, Waters

What is Biomanufacturing?

Video courtesy of the NIIMBL website

Biopharmaceuticals are increasingly showing promising results in treating some of the most prevalent and debilitating diseases affecting human health. But manufacturing of biopharmaceuticals is not without large-scale operational and technological challenges.

NIIMBL, will focus its efforts on driving down the cost and risks associated with manufacturing advanced cell and gene therapies for biopharmaceutical production.

UGA Organizational Meeting March 14, 2017

Update May 2017

Education/Workforce Development Needs Survey Results. Surveys were conducted at five Regional Meetings held throughout the U.S., attended by participants from industry, academia, and government and non-profit agencies.

Click her to view survey criteria.

Click here to view Education / Workforce Development Needs Survey Results

Project Calls:

Quick Start Project Call, DUE January 2018

Project Call 1.0 requests proposals for projects that address technology and/or workforce development issues in biomanufacturing. The Request for Proposals details several topic areas of interest in each of these categories. These topic areas were identified with input from Industry members.

Project Call 1.0. VIEW DETAILS/FAQ

VIEW Current NIIMBL Newsletter